Equities

Saniona AB

Saniona AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)3.89
  • Today's Change-0.24 / -5.81%
  • Shares traded3.05m
  • 1 Year change-47.22%
  • Beta1.0242
Data delayed at least 15 minutes, as of Jun 14 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

  • Revenue in SEK (TTM)20.71m
  • Net income in SEK-83.30m
  • Incorporated2014
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ultimovacs ASA0.00-174.90m291.95m25.00--1.15-----5.17-5.170.007.530.00----0.00-44.31-28.80-50.09-31.12------------0.0136-------12.78---45.35--
Ascelia Pharma AB0.00-88.76m311.58m13.00--5.12-----2.63-2.630.001.800.00----0.00-65.17---78.39--------------0.2302------16.72------
Bactiquant A/S18.56m-19.76m345.55m----15.90--18.62-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
Medivir AB7.73m-96.52m348.49m10.00--1.65--45.06-1.46-1.460.10281.890.032--1.56773,300.00-40.00-28.91-47.20-34.77-888.81-467.42-1,248.18-675.96----0.0482--73.16-20.39-0.6275---47.96--
INIFY Laboratories AB3.42m-51.35m352.57m23.00--4.83--103.21-1.15-1.150.07681.640.0322.990.6608---48.10---48.10--76.42---1,503.10------0.00--------------
Magle Chemoswed Holding AB170.01m12.23m360.72m78.0029.502.2314.402.121.131.1315.7414.950.60680.4938.302,179,628.004.362.525.863.5290.5885.677.193.920.63566.350.3081--17.009.9733.07---6.34--
Herantis Pharma Oyj0.003.15m376.54m10.00132.067.08119.59--0.01260.01260.000.23440.00----0.004.31-80.466.16-104.37------------0.0073------103.00------
Lytix Biopharma AS3.92m-86.42m386.33m10.00--6.28--98.45-2.16-2.160.09811.260.0368--0.4091399,100.00-80.96-56.91-94.07-65.83-----2,202.36-771.78----0.0095---63.8263.94-56.77------
Saniona AB20.71m-83.30m432.72m23.00--15.87--20.89-1.09-1.090.26290.24510.1726--5.63900,521.80-69.41-59.16-127.89-70.15-136.88-970.05-402.20-1,483.55---3.850.71--10.19-21.0554.71---34.94--
Xbrane Biopharma AB190.97m-361.27m441.26m75.00--1.12--2.31-1.33-1.580.69780.25770.24651.34332.122,053,430.00-46.63-40.98-78.01-67.2415.43---189.18-364.401.43-31.130.3693--314.3363.42-91.10--60.02--
Bergenbio ASA512.28k-151.93m444.82m16.00--333.46--868.32-0.1849-0.18490.00030.03470.0047--0.048520,840.00-139.81-66.15-275.19-78.74-----29,658.54-11,419.44----0.00---9.00-31.4336.98------
Enzymatica AB (publ)47.29m-53.67m471.60m18.00--5.62--9.97-0.3247-0.32470.28660.48410.32691.386.48---37.11-27.36-39.16-33.9864.2565.08-113.50-66.12---23.260.2502--4.00-0.638227.57--7.02--
Mendus AB (publ)0.00-107.07m472.37m28.00--0.6023-----3.15-3.150.0015.570.00----0.00-16.09-18.84-17.35-20.21-------28,474.53----0.0348---100.00--26.78------
Lifecare ASA12.87m-34.67m472.83m32.00--5.96--36.75-0.2454-0.24540.0920.41630.1621--4.90408,943.10-43.60-40.00-49.97-45.26-----269.03-175.53----0.1812---40.8830.29-101.74------
Hamlet BioPharma AB0.00-33.41m521.28m7.00--9.01-----0.2326-0.23260.000.4530.00-------63.45-83.52-69.09-107.84------------0.00-------18.87--78.01--
Initiator Pharma A/S0.00-33.98m539.64m3.00--16.01-----0.6241-0.62410.000.63690.00----0.00-70.60-68.27-73.77-74.02------------0.00------27.95------
Data as of Jun 14 2024. Currency figures normalised to Saniona AB's reporting currency: Swedish Krona SEK

Institutional shareholders

3.24%Per cent of shares held by top holders
HolderShares% Held
Tredje AP-fondenas of 29 Aug 20232.23m2.01%
Handelsbanken Fonder ABas of 31 May 2024683.73k0.62%
SEB Investment Management ABas of 30 Apr 2024419.02k0.38%
FCG Fonder ABas of 31 Dec 2023187.71k0.17%
Skandia Investment Management ABas of 28 Mar 202429.63k0.03%
Storebrand Asset Management ASas of 31 Jan 202427.33k0.03%
Case Kapitalf�rvaltning ABas of 30 Nov 202218.70k0.02%
Abante Asesores Gesti�n SGIIC SAas of 30 Jun 20230.000.00%
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.